Guggenheim Downgrades Allergen (AGN) to Neutral on Takeover
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Wall St tumbles as hot CPI boosts rate-hike bets; banks, AI stocks weigh
- Oil prices steady after gains on Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Tweet
Share
E-mailGet Alerts AGN Hot Sheet
Price: $193.02 --0%
Rating Summary:
8 Buy, 20 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 10 | New: 34
Rating Summary:
8 Buy, 20 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 10 | New: 34
Join SI Premium – FREE
Guggenheim downgraded Allergen (NYSE: AGN) from Buy to Neutral but raises its price target to $220.00 following the Actavis (ACT) acqusition.
For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $209.20 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Downgrades Albertsons Companies Inc. (ACI) to Underperform
- Mizuho Downgrades Lantheus Holdings (LNTH) to Neutral
- Goldman Sachs Downgrades Carrier Global (CARR) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
